Press Ventures Advances Application for U.S. EPA License to Sell Designation
22 October 2013 - 8:23AM
Marketwired
Press Ventures Advances Application for U.S. EPA License to Sell
Designation
WARSAW, POLAND--(Marketwired - Oct 21, 2013) - Press
Ventures Inc. (OTCQB: PVEN) ("Press Ventures" or the
"Company"), through its wholly-owned Polish subsidiary
Biosafety Systems, Inc. Sp z o.o., is pleased to announce that it
has engaged with the U.S. Environmental Protection Agency (EPA)
office of pesticide programs, antimicrobial division in an effort
to advance its application submissions to receive a "license to
sell" designation for its patented Cedar Leaf Oil Diffusion
("CLO-D") biosafety system within the United States.
"Our initial exchange with the EPA was both informative and
encouraging resulting in the identification of specific protocols
that map out the entire pre-application, application submission,
EPA evaluation, and EPA approval process for the CLO-D biosafety
system," stated Mr. Edward Denkiewicz, Press Ventures CEO. "To
assist in this process, we have engaged an industry expert to guide
us with the preparation and submission of all documents needed for
the next pre-application submission and meeting with the EPA that
will ascertain the appropriate path for CLO-D's EPA registration
and its commercial application."
Mr. Denkiewicz goes on to further explain, "The pre-submission
application with the EPA will serve to provide clarity and guidance
to the Company in its final application with the EPA. Once the
pre-submission application has been filed, a thorough review will
be conducted by the EPA Product Manager with the outcome of that
analysis providing the framework for our final EPA submission to
receive a 'license to sell' for its patented antimicrobial solution
systems within the United States. The Company has already
taken the next steps of this process by submitting an eligible fee
waiver application that should result in a 75% reduction in the
significant EPA application fees."
The Company's License to Sell application will be driven by the
following parameters as detailed in the US EPA's Office of
Pesticide Programs policies:
1). That the patented CLO-D, "cedar leaf oil-diffusion" is
categorized by the EPA as an Antimicrobial Pesticide for "public
health."
Public health antimicrobial products are those products that
bear a claim to control pesticide microorganisms that pose a threat
to human health, and whose presence can not be readily observed by
the user, including but not limited to, microorganisms infectious
to man in any area of the inanimate environment. A product
makes a public health claim if one or more of the following
apply:
- a claim is made for control of specific microorganisms or
classes of microorganisms that are directly or indirectly
infectious or pathogens to man (or both man and animals).
- a claim is made for the pesticide product as a sterilant,
disinfectant, virucide, sanitizer, or tuberulculocide against
microorganisms that are infectious or pathogenic to man.
- a claim is made for the pesticide product as a fungicide
against fungi infectious or pathogenic to man, or the product does
not clearly state that it is intended for use only against
non-public health fungi.
- a claim is made for the pesticide product as a microbiological
water purifier or microbial purification system.
- a non-specific claim is made that the pesticide product will
beneficially impact or affect public health at the site of use or
in the environment in which applied, and:
The pesticide product contains one or more ingredients that,
under the criteria in 40 CFR 153.125 (a) is an active ingredient
with respect to a public health microorganism and there is no other
purpose for the ingredient in the product; or The pesticide product
is similar in composition to a registered pesticide product that
makes explicit antimicrobial public health claims.
2). That CLO-D will require a "new active ingredient"
registration under the Federal Insecticide, Fungicide, and
Rodenticide Act (FIFRA) and additionally under the Federal Food,
Drug, and Cosmetic Act (FFDAC).
Mr. Denkiewicz concluded, "While the process to have CLO-D
licensed by the U.S. EPA is certainly an intensive one, and is
expected to take up to 18 months to complete, we are very
encouraged that under the guidelines as we have come to interpret
them and as depicted in our direct discussion with EPA
representatives, that our intent to have CLO-D receive an
EPA-backed license as an Antimicrobial Pesticide suitable for both
human and agricultural applications is both achievable and
strategic. The benefit to our Company is that we will not be
required to submit dual applications for human and agricultural
applications. Clearly this represents a substantial cost
savings to the Company in application fees and human resources
required to assemble and file such applications. We are
certainly keen to continue the supplementary document submission
process with the U.S. Environmental Protection Agency and to
advance our initiative with them to receive this critical
endorsement from one the most important and respected governing
bodies in American industry."
About Press Ventures
Press Ventures holds the worldwide rights to the patented
Cedar Leaf Oil Diffusion ("CLO-D") technology for the use of
natural products to kill bacteria, mold, and viruses in
buildings. The patented CLO-D technology has been shown to be
capable of killing many deadly bacterial and viral substances such
as anthrax and H1N1 in buildings while they are still
occupied. The CLO-D technology has been laboratory and field
tested and the Company believes that use of the technology can
provide a marked improvement in air quality and eliminate many of
the most dangerous airborne bacteria, viruses, and
pollutants. For additional information about CLO-D
technology and Press Ventures, please visit
www.biosafetysystemsinc.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as
that term is defined in Section 27(a) of the Securities Act of
1933, as amended, and Section 21(e) of the Securities Exchange Act
of 1934, as amended. Statements in this press release
that are not purely historical are forward-looking statements and
include any statements regarding beliefs, plans, expectations or
intentions regarding the future. Such forward-looking
statements include, among other things, the EPA review and approval
process, registration requirements under FIFRA and FFDAC,
approval of EPA license to sell, capability of the Company's
technology and market information. Actual results could differ
from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the
inherent uncertainties associated with developing new products or
technologies and operating as a development stage company, our
ability to retain important members of our management team and
attract other qualified personnel, our ability to raise the
additional funding we will need to continue to pursue our business
and product development plans, our ability to develop and
commercialize products based on our technology platform, and
market conditions. These forward-looking statements
are made as of the date of this news release, and we assume no
obligation to update the forward-looking statements, or to update
the reasons why actual results could differ from those
projected in the forward-looking statements. Although we
believe that any beliefs, plans, expectations and
intentions contained in this press release are reasonable, there
can be no assurance that any such beliefs, plans, expectations or
intentions will prove to be accurate. Investors should consult
all of the information set forth herein and should also refer to
the risk factors disclosure outlined in the reports and other
documents we file with the SEC, available at
www.sec.gov.
Investor Relations Contact: 1-888-709-1550
IR@kingstonir.net
Press Ventures (CE) (USOTC:PVEN)
Historical Stock Chart
From Nov 2024 to Dec 2024
Press Ventures (CE) (USOTC:PVEN)
Historical Stock Chart
From Dec 2023 to Dec 2024